Virbac operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Virbac with three other
companies in this sector in France:
sales of 350.35 million Euro [US$415.60 million]
of which 76%
(775.77 million Euro [US$920.25 million]
of which 48%
was X-rays), and
(614.49 million Euro [US$728.93 million]
of which 51%
was Non-Proprietary Homeopathic Medicines).
Virbac reported sales of 871.83 million Euro (US$1.03 billion)
December of 2016.
increase of 2.3%
versus 2015, when the company's sales were 852.62 million Euro.
Sales at Virbac have increased during each of the previous five years
(and since 2011, sales have increased a total of 40%).
Sales of Companion Animals saw an increase
that was more than double the company's growth rate: sales were up
6.4% in 2016, from
477.80 million Euro to 508.20 million Euro.
Not all segments of Virbac experienced an increase in sales in 2016:
sales of Other fell 12.7% to 8.90 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).
Virbac also experienced decreases in sales in
Food Productsing Annimal (down 2.7% to 354.70 million Euro)